Bio-Rad Laboratories [BIO] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Bio-Rad Laboratories
NYSE
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bio-Rad Laboratories wins in 8 metrics, Abbott Laboratories wins in 11 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bio-Rad Laboratories | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.55 | 16.89 | Abbott Laboratories |
| Price-to-Book Ratio | 1.16 | 4.63 | Bio-Rad Laboratories |
| Debt-to-Equity Ratio | 19.73 | 26.50 | Bio-Rad Laboratories |
| PEG Ratio | -0.24 | 0.46 | Bio-Rad Laboratories |
| EV/EBITDA | 20.23 | 21.02 | Bio-Rad Laboratories |
| Profit Margin (TTM) | 12.50% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 12.19% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 12.19% | 19.73% | Abbott Laboratories |
| Return on Equity | 4.59% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 1.59% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $266.20M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -11.12% | 19.49% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 3.22 | 5.43 | Bio-Rad Laboratories |
| Enterprise Value | $8.30B | $240.70B | Abbott Laboratories |
| EV/Revenue Ratio | 3.25 | 5.58 | Bio-Rad Laboratories |
| Gross Profit Margin (TTM) | 52.99% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $92 | $25 | Bio-Rad Laboratories |
| Earnings per Share (Diluted) | $11.09 | $7.97 | Bio-Rad Laboratories |
| Beta (Stock Volatility) | 0.97 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Bio-Rad Laboratories vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | 1.20% | 12.58% | 6.05% | 21.44% | 30.13% | -6.34% |
| Abbott Laboratories | -0.63% | 0.78% | 1.82% | 0.11% | 2.25% | 18.64% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | -11.12% | -28.78% | -46.04% | 119.48% | 234.01% | 462.39% |
| Abbott Laboratories | 19.49% | 32.22% | 22.75% | 221.29% | 431.14% | 556.86% |
News Based Sentiment: Bio-Rad Laboratories vs Abbott Laboratories
Bio-Rad Laboratories
News based Sentiment: MIXED
October brought a blend of positive and negative developments for Bio-Rad Laboratories. While the stock experienced a short-term decline and a downgrade, strong institutional ownership and a positive analyst outlook suggest underlying confidence. The upcoming earnings report on October 29th will be a key catalyst for determining the company's future direction.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: Bio-Rad Laboratories vs Abbott Laboratories
| Metric | BIO | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $8.38B | $234.39B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 214,510 | 5,683,430 |
| 90 Day Avg. Volume | 238,283 | 5,498,563 |
| Last Close | $309.17 | $133.74 |
| 52 Week Range | $211.43 - $387.99 | $110.86 - $141.23 |
| % from 52W High | -20.31% | -5.30% |
| All-Time High | $832.70 (Aug 30, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -62.87% | -6.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.07% |
| Quarterly Earnings Growth | 0.02% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.32% |
| Operating Margin (TTM) | 0.12% | 0.20% |
| Return on Equity (TTM) | 0.05% | 0.31% |
| Debt to Equity (MRQ) | 19.73 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $263.42 | $29.05 |
| Cash per Share (MRQ) | $50.76 | $4.18 |
| Operating Cash Flow (TTM) | $534.20M | $9.04B |
| Levered Free Cash Flow (TTM) | $223.40M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Bio-Rad Laboratories vs Abbott Laboratories
| Metric | BIO | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.55 | 16.89 |
| Forward P/E | 26.22 | 26.08 |
| PEG Ratio | -0.24 | 0.46 |
| Price to Sales (TTM) | 3.22 | 5.43 |
| Price to Book (MRQ) | 1.16 | 4.63 |
| Market Capitalization | ||
| Market Capitalization | $8.38B | $234.39B |
| Enterprise Value | $8.30B | $240.70B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.25 | 5.58 |
| Enterprise to EBITDA | 20.23 | 21.02 |
| Risk & Other Metrics | ||
| Beta | 0.97 | 0.70 |
| Book Value per Share (MRQ) | $263.42 | $29.05 |
Financial Statements Comparison: Bio-Rad Laboratories vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIO | ABT |
|---|---|---|
| Revenue/Sales | $585.40M | $10.36B |
| Cost of Goods Sold | $279.40M | $4.47B |
| Gross Profit | $306.00M | $5.89B |
| Research & Development | $73.50M | $716.00M |
| Operating Income (EBIT) | $23.70M | $1.69B |
| EBITDA | $98.50M | $2.66B |
| Pre-Tax Income | $83.40M | $1.78B |
| Income Tax | $19.40M | $453.00M |
| Net Income (Profit) | $64.00M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIO | ABT |
|---|---|---|
| Cash & Equivalents | $521.40M | $6.53B |
| Total Current Assets | $3.04B | $23.15B |
| Total Current Liabilities | $506.60M | $13.00B |
| Long-Term Debt | $1.33B | $12.74B |
| Total Shareholders Equity | $6.68B | $49.06B |
| Retained Earnings | $7.48B | $47.72B |
| Property, Plant & Equipment | $681.70M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIO | ABT |
|---|---|---|
| Operating Cash Flow | $156.00M | $1.42B |
| Capital Expenditures | $-34.40M | $-484.00M |
| Free Cash Flow | $95.50M | $933.00M |
| Debt Repayment | $-100,000 | $-1.00B |
| Common Stock Repurchase | $-101.90M | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BIO | ABT |
|---|---|---|
| Shares Short | 1.11M | 18.07M |
| Short Ratio | 4.84 | 3.68 |
| Short % of Float | 0.06% | 0.01% |
| Average Daily Volume (10 Day) | 214,510 | 5,683,430 |
| Average Daily Volume (90 Day) | 238,283 | 5,498,563 |
| Shares Outstanding | 28.01M | 1.73B |
| Float Shares | 21.67M | 1.73B |
| % Held by Insiders | 0.16% | 0.01% |
| % Held by Institutions | 0.90% | 0.81% |
Dividend Analysis & Yield Comparison: Bio-Rad Laboratories vs Abbott Laboratories
| Metric | BIO | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |